KROS Stock Analysis: Buy, Sell, or Hold?
KROS - Keros Therapeutics, Inc. Common Stock
$17.91
-0.08 (-0.44%)
▼
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 25, 2026
23d
Get Alerted When KROS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: KROS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: KROS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: KROS is currently trading at $17.91, which is considered oversold relative to its 30-day fair value range of $18.11 to $20.05.
Technical Outlook: Technically, KROS is in a strong uptrend. The price is currently testing key support at $17.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KROS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $23.50 (+31.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KROS is in a strong uptrend. The price is currently testing key support at $17.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KROS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $23.50 (+31.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$18.11 -
$20.05
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
Protect Your Profits
Holding KROS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.2% below Wall St target ($23.50)
- CAUTION: Recommendation downgraded due to -6.7% 5-day decline
Fair Price Analysis
30-Day Fair Range
$18.11 -
$20.05
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$2.07
(11.5%)
Support & Resistance Levels
Support Level
$17.65
Resistance Level
$19.94
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-6.09
Wall Street Target
$23.50
(+31.2%)
Revenue Growth (YoY)
3575.8%
Profit Margin
26.1%
Last updated: February 01, 2026 1:00 AM ET
Data refreshes hourly during market hours. Next update: 2:00 AM
Data refreshes hourly during market hours. Next update: 2:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KROS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Adar1 Capital Management…
SELL
5389264 shares
2025-10-15
Pontifax Management 4 G.…
SELL
4787331 shares
2025-10-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 54 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$486 | 45 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$500 | 62 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$91 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
Advanced KROS Option Strategies
Professional options setups generated by AI based on today's KROS price and gamma walls.
